The deal provides non-dilutive capital and validates KIO-301's global potential, but the $1 million upfront is modest for an $11M market cap company. Monitor for progress toward the global Phase 3 trial and any updates on KIO-104 development, which is now the primary internal focus.
Price Chart
Executive Summary
Kiora Pharmaceuticals has entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical (CKD) for the development and commercialization of KIO-301 in South Korea. The deal includes a $1 million upfront payment and potential milestone payments and royalties, completing Kiora's global partnership network for KIO-301. This is a positive validation of KIO-301's potential and provides non-dilutive capital, but the financial impact is modest given the early stage and small market size.
Key Financial Metrics
Key Facts
- Kiora licensed exclusive South Korean rights for KIO-301 to Chong Kun Dang Pharmaceutical (CKD) for ophthalmic indications.
- Kiora receives a $1 million upfront payment and is eligible for development, regulatory, and sales milestone payments plus double-digit royalties.
- CKD will be responsible for development and commercialization in South Korea, and the partners plan a single global Phase 3 trial for KIO-301 in retinitis pigmentosa.
- This deal completes Kiora's global partnership network for KIO-301, covering the U.S., Europe, Japan, China, and now South Korea.
- Kiora will focus internal resources on advancing KIO-104 and evaluating pipeline expansion opportunities.
Financial Impact
$1 million upfront payment with potential milestone payments and double-digit royalties on future South Korean sales.
Risk Factors
- KIO-301 is still in clinical development and may fail to gain regulatory approval.
- Milestone and royalty payments are contingent on future development and commercial success, which is uncertain.
- The South Korean market for retinitis pigmentosa is small (estimated 10,000 patients), limiting peak revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001372514-26-000077 |
| Exhibit: ex991-pressreleaseckdaugus.htm | 0001372514-26-000077 |
| Document: kprx-20260819.htm | 0001372514-26-000077 |
| Document: 0001372514-26-000077-index-headers.html | 0001372514-26-000077 |
| Document: 0001372514-26-000077-index.html | 0001372514-26-000077 |
| Document: 0001372514-26-000077.txt | 0001372514-26-000077 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 7w ago | 8-K | $2.51 $2.50 | ▼ −0.40% | ▼ −2.37% | $2.20 (−12.29%) |
Aug 19, 2026 9w ago | 8-K | $2.60 $2.67 | ▲ +2.69% | ▲ +4.64% | $2.20 (−15.33%) |
Aug 7, 2026 11w ago | 8-K | $2.64 $2.55 | ▼ −3.41% | ▼ −3.01% | $2.20 (−16.61%) |
Jun 18, 2026 18w ago | 8-K | $2.53 $2.55 | ▲ +0.79% | ▲ +0.26% | $2.20 (−12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers